DD

Business profile & competitive position

DuPont de Nemours, Inc. operates in the Basic Materials sector, specifically the Chemicals industry. After separating its Electronics business and treating Electronics, Aramids and the historical M&M operations as discontinued, the company now reports through two segments: Healthcare & Water Technologies and Diversified Industrials. Its continuing operations supply differentiated technologies such as medical packaging and devices, water filtration and purification products, building-envelope and interior solutions, industrial adhesives, lubricants, engineered shapes and printing plates.

The portfolio is protected by a substantial patent estate—about 6,100 patents and patent applications globally, with roughly 4,700 tied to continuing operations and more than 70% of that continuing-operations estate having a remaining term of more than five years. That intellectual-property base is the most concrete evidence of product differentiation. Yet differentiation on paper has not translated into strong current profitability: reported net margin is only 0.7% and return on equity is 0.3%. Those figures imply that whatever technical moat exists is being offset by cost pressures, liability burdens or portfolio-transition noise, leaving very little residual earnings power for shareholders right now. In other words, DuPont’s competitive position is more about specialty technology than about pricing power at the bottom line today.

Financial posture

DuPont currently carries a market capitalization of $17.8 billion and trades at a trailing P/E of 286.2. With a net margin of just 0.7% and an ROE of 0.3%, that multiple is being set by expectations of a recovery rather than by current earnings. At a share price of $131.64, the implied earnings yield is below 0.35%, which is consistent with a company whose net income has been depressed relative to its asset base and revenue.

The stock’s beta is 1.08, suggesting price movements have been roughly in line with the broader market. Near-term technical context shows the stock below its 50-day EMA of $138.54, with an RSI of 36.1. That RSI level is not yet deeply oversold, but it does indicate that recent price momentum has weakened relative to the past 14 sessions. The financial posture, then, is one of a specialty-chemical company trading on a high headline multiple while its current margins and returns are unusually thin.

Strategic priorities & outlook

DuPont’s most recent 10-K filing outlines a near-term agenda dominated by portfolio cleanup and capital return rather than aggressive expansion. The stated priorities are:

• Complete the previously announced sale of the Aramids business to Arclin, expected around the end of the first quarter of 2026, subject to customary closing conditions and regulatory approvals.
• Realize the intended benefits of the Electronics Separation, including the intended tax treatment and the contractual allocation of certain liabilities to Qnity.
• Execute the $2 billion share buyback authorization announced on November 6, 2025.
• Manage the arrangement to share future eligible PFAS costs among DuPont, Corteva and Chemours, including related litigation and remediation exposures.

Operationally, the company realigned into two reportable segments effective in the fourth quarter of 2025 and recast financial statements as if the M&M, Aramids and Electronics separations had occurred on January 1, 2023. As of December 31, 2025, DuPont had subsidiaries in about 50 countries, manufacturing operations in about 20 countries and approximately 15,000 employees worldwide, including roughly 1,700 dedicated to the Aramids business. The message from management is clear: simplify the portfolio, return cash to shareholders and ring-fence legacy liabilities.

Macro & geopolitical exposure

As a diversified chemicals company with global manufacturing and sales, DuPont is exposed to the standard macro and geopolitical risks of the Basic Materials/Chemicals industry. These include feedstock and energy-price volatility, freight and logistics disruptions, currency translation effects from operations across roughly 50 countries, and environmental regulation. The chemicals industry also faces heightened regulatory scrutiny around persistent chemicals and emissions, which in DuPont’s case maps to the ongoing PFAS-related litigation and remediation cost-sharing arrangement. Trade policy, tariffs and cross-border supply-chain rules matter as well, because chemical production is capital-intensive and often tied to regional feedstock advantages. Finally, demand from construction, industrial manufacturing, healthcare and water infrastructure will shape revenue visibility, especially now that the Electronics segment has been separated.

Recent developments

Recent headlines have kept DuPont’s water, cleanroom materials and sustainability platforms in view:

• August 20, 2026 (GlobeNewswire): Flow Cleanrooms & Supply expanded availability of DuPont™ Tyvek® IsoClean® and DuPont™ Tyvek® 400 garments, suggesting continued channel demand for contamination-control apparel.
• August 18, 2026 (Zacks): A sector note highlighted diversified chemical stocks as positioned to gain amid stable end-market demand, placing DuPont in a broader industry context.
• August 17, 2026 (Zacks): DuPont’s MemCor MBR system was selected for a major plant upgrade in Australia, reinforcing the water-treatment growth narrative.
• August 13, 2026 (PRNewswire): The DuPont Direct Lithium Extraction team was named a 2026 Sustainability Squad winner by the Business Intelligence Group, pointing to another potential application where DuPont’s separation technologies could see demand.

DuPont’s next earnings report is scheduled for November 5, 2026, before the market opens, with a current consensus EPS estimate of $1.87.

Earnings behavior & post-earnings drift

DuPont has delivered an unblemished beat rate over the last eight reported quarters: 8 out of 8, or 100%. The average earnings surprise across that span is 171.1%, and the stock has averaged a 5-day post-earnings drift of +2.83%, classified as an upward drift. Those outsized average surprises are flattered by periods when reported EPS dramatically exceeded low estimates, but the pattern itself is consistent: management has consistently cleared the bar that sell-side analysts set.

The most recent four quarters illustrate both the magnitude and the variability:

• August 4, 2026: EPS of $1.88 vs. an estimate of $1.76, a 6.8% surprise. The stock rose 3.11% the next day and 1.09% over the following five days.
• May 5, 2026: EPS of $1.65 vs. an estimate of $0.4881, a 238% surprise. The stock rose 1.69% the next day and 2.64% over the following five days.
• February 10, 2026: EPS of $1.38 vs. an estimate of $1.29, a 7% surprise. The stock rose 4.25% the next day and 3.88% over the following five days.
• November 6, 2025: EPS of $3.27 vs. an estimate of $0.4656, a 602.3% surprise. The stock rose 1.66% the next day and 3.70% over the following five days.

The message is that even when next-day reactions look modest, the stock has typically drifted higher over the following week after results. Heading into the November 5, 2026 report, the consensus EPS estimate is $1.87. Whether the 100% beat streak continues depends on how the newly slimmed portfolio performs against that estimate, and whether any PFAS or separation-related charges materialize in the quarter.

For a deeper dive into how institutional analysts currently view DuPont’s risk/reward profile, valuation assumptions and earnings model, consult the full institutional verdict on the company.